A clinical study was conduct in HIV-infected children to evaluate the prophylactic doses of cotrimoxazole [sulfamethoxazole (SMX) and trimethoprim (TMP)] advised by the WHO.
Introduction
Prevention of mother-to-child human immunodeficiency virus (HIV) transmission has proven its efficiency; however, due to the lack of operational access to this intervention, paediatric infection still takes place. Of HIV-infected children, 35% die before their first birthday in the absence of any intervention [1, 2] . For all HIV-infected children younger than 2 years, of all immune status, the 2010 World Health Organization (WHO) revised guidelines advised a combined antiretroviral treatment (cART) from the beginning. This treatment was extended to all children in 2015 [3] .
Despite the advent of antiretroviral drugs, opportunistic infections (OIs) persist to induce considerable mortality and morbidity in HIV-infected children, especially in Africa [4] . Cotrimoxazole (TMP and SMX) has been used to avoid OIs in HIV-infected children since 2000 [5] . The efficacy of cotrimoxazole in the prevention of Pneumocystis jirovecii pneumonia was first shown by Hughes et al. in a randomized trial in 1977 [6] and confirmed thereafter in numerous randomized or observational studies [7, 8] . A clinical trial was carried out among children after infancy in Lusaka and Zambia. This study showed that daily cotrimoxazole prophylaxis (240 mg daily for children from 1 to 5 years and 480 mg for children above 5 years) reduces mortality and morbidity even if 60-80% of common bacterial infections have an invitro resistance to cotrimoxazole [9] . Indeed, this randomized controlled trial on 534 infected children (average age: 4.4 years; 32% from 1 to 2 years and 15% older than 10 years) showed a 43% mortality decrease and 23% hospital admission decrease. The spectrum of microbial prophylactic efficiency progressively extended to several bacterial pathogens, Toxoplasma gondii [10, 11] , and more recently (to a lesser extent) to plasmodium [12] [13] [14] . The use of cotrimoxazole in children therefore plays a major role in the care of HIV-infected children [15] .
Renal excretion is the predominant way of elimination for both TMP and SMX [16, 17] . Renal secretion of unchanged drug is the elimination pathway for the rest of TMP [17] . SMX is metabolized by cytochrome P450 (CYP) 2C9 into SMX-hydroxylamine. It is then converted to N-acetoxy-SMX by N-acetyltransferase 1 (NAT1) [18] and 2 (NAT2) [19, 20] . SMX-hydroxylamine (SMX-HA) is a precursor of reactive metabolites mediating hypersensitivity reactions. Therefore any modifications in the abundance or activity of NAT1 or NAT2 could increase the exposure of toxic metabolite and subsequently may increase the risk of toxicity [19] . Many therapeutic drugs have the NAT2 in their elimination pathways [21, 22] . SMX pharmacokinetics in humans can be affected by the alteration of NAT1 and/or NAT2 acetylator status created by polymorphisms in the NAT2 gene [23] , and this alteration can also have an impact of defining susceptibility to sulfamethoxazole toxicity [18] . Moreover other in-vivo studies indicate that NAT1 and NAT2 could also directly metabolize SMX [18, 23] .
However, prophylactic cotrimoxazole doses are very variable according to different references, as shown in Table 1 . These discrepancies stem from the lack of pharmacokinetic (PK) data available in children and lack of preventive and non-toxic concentration targets. There are few pharmacokinetic data in neonates [24] and children [25] , and the age group 6 months-3 years is poorly described in terms of workforce. Thus, in 1982, Springer et al. [24] were interested in the pharmacology of TMP-SMX in newborn infants (n = 12) and Siber et al. addressed SMX-TMP PK in an age range from 0.2-82 years [26] but only 11 children (0.2-9 years) were included in that study. In 1984, Hoppu et al. studied the difference between children and adults in TMP pharmacokinetics (1-9 years: n = 5) [27] and in 1987 they investigated the differences in the pharmacokinetics of TMP in terms of age and the need to revise doses in children (1.5-3 years: n = 7; 8-10 years: n = 9) [25] . Finally, in 1989, Hoppu et al. were interested in modification of TMP pharmacokinetics after the newborn period (n = 6) [28] . Data for SMX are therefore very rare. For TMP, estimated clearances range from 0.11 l h À1 kg À1 to 0.19 l h À1 kg À1 , distribution volumes from 0.9 l kg À1 to 2.9 l kg À1 and half-lives from 3.8 to 19 h.
In West African countries, a randomized controlled trial (ANRS 12206 MONOD project) was conducted in HIV-infected children. These children had a treatment of 12-month cART combined to cotrimoxazole prophylaxis initiated before the age of two. This trial was aimed to assess an easier once daily cART based on efavirenz than a twice daily treatment based on lopinavir/ritonavir.
Within this project, we appended a pharmacokinetic substudy whose aims were: (i) to describe the pharmacokinetics of SMX and TMP, (ii) to identify the impact of covariates on cotrimoxazole pharmacokinetics, and (iii) to define appropriate dosing regimens in order to evaluate whether a dosing adjustment is necessary in the ANRS 12206 MONOD trial cohort of HIV-infected children.
Methods

Study design
MONOD-ANRS-12206 was conducted in Ouagadougou, Burkina-Faso and Abidjan, Côte d'Ivoire (ClinicalTrial.gov registry number: NCT01127204) [29] . This randomized, non-inferiority, and open label phase 3 trial was approved by the 'Comité d'Ethique pour la Recherche en santé du Burkina Faso', and the 'Comité National d'Ethique et de la Recherche en Côte d'Ivoire'. Children received a triple therapy based on lopinavir twice daily as an initial ART for 12 months. If the viral suppression was confirmed (HIV-1 RNA < 500 copies ml À1 ) they were then randomized in two groups at 13 months. The first group continued to have lopinavirbased therapy. The second switched to an EFV strategy once daily until 25 months. In line with the current WHO recommendations, all the children received once daily prophylaxis of opportunistic infections by cotrimoxazole (Table 1) .
Pharmacokinetic sub-study procedures
Children's data were collected from the beginning of ART treatment and then during each visit every month until 25 months. Age, sex, body weight (BW), creatinine, aspartate amino transferase (ASAT) and alanine amino transferase (ALAT) were registered as demographic and clinical variables. Time of administration and time of sampling were also recorded. Pharmacokinetic samples were taken during the initial treatment cohort at 6th month (M6), 19th month (M19) and 25th month (M25) visits. The pharmacokinetic parameters of each molecule received by children were measured by one or two samples per child at each visit and made at random times. Drug-taking schedules were collected specifically to allow estimation of the different pharmacokinetic parameters. Different time samples were defined as follows:
• T0, just before taking the drugs;
• T1, 0:30 to 1:30 h after taking;
• T2, 2:30 to 5 h after taking;
• T3, about 8 h after taking.
The children's samples were frozen and stored at À80°C.
Analytical methods
To determine drug concentrations in plasma, blood samples were collected into heparin tubes. Centrifugation was used to isolate plasma (3200 g for 10 min) and stored at À80°C until analysis. To determine the TMP and SMX concentrations in plasma, a validated method was used on a highperformance liquid chromatograph with UV detector (HPLC, Waters, Barcelona, Spain). A Kinetex C18 analytical column (100 × 3 mm, 2.6 μm) was used. Drug was extracted from plasma with ethyl acetate by liquid extraction. The mobile phase consisted of a gradient elution with 50 mM ammonium formate, pH = 3.8. The method was linear over the range of 0-20 mg l À1 for TMP and of 0-200 mg l À1 for SMX.
The lower limit of quantification (LLOQ) for TMP was 0.025 mg l À1 and 0.25 mg l À1 for SMX. The value of intraand inter-day accuracy and precision ranged from À11.9% to 13.02 for SMX and from À5.75% to 9.8 for TMP. For TMP, the recovery from plasma was 88% and 90% for SMX. The Association for Quality Assessment in Therapeutic Drug Monitoring organized an external quality assurance programme that was followed by our laboratory.
Pharmacogenetic studies DNA extraction. Genomic DNA was isolated from the saliva collected with the Oragen Kit buffer (DNA Genotek, Ottawa, Canada), using the PrepIT DNA extraction kit according to the manufacturer's instructions (DNA Genotek, Ottawa, Canada).
Variant selection and genotyping. Single nucleotide protein (SNPs) were selected on the basis of (i) previously reported association with SMX response or with known functional impacts on SMX metabolism, and (ii) a minor allelic frequency (MAF) > 5% to ensure sufficient power for a gene candidate approach. A total of nine SNPs were genotyped:
• rs2256871 in CYP2C9*9 and rs7900194 in CYP2C9*8 [19, 30] ; • rs1057126 and rs15561 in NAT1 [31, 32] ; • rs1041983, rs1801280, rs1799929, rs1799930 and rs1208 in NAT2 [33, 34] .
Quantitative PCR with TaqMan probes was used for CYP2C9 genotyping and Big Dye sequencing PCR for NAT1 and NAT2. For NAT1, the technique used is that described by Hsieh et al. [35] ; and for NAT2 as described by Touré et al. [34] .
Population pharmacokinetic analysis and modelling
NonMEM software (version 7, ICON Development Solution, Ellicott City, MD, USA) was used to perform a nonlinearmixed effects modelling [36] . The procedure to fit all the models was the first order conditional estimation one.
The first step to build the pharmacokinetic model for TMP and SMX consisted in developing a structural model. The second step was to add inter-individual variability of parameters. The last step was to test the influence of patient characteristics on the changes in the parameters (covariate models).
Structural models. The data were fitted with one-or twocompartment models with linear or nonlinear elimination in order to determine the disposition characteristics of TMP and SMX. The description of the inter-individual variability of the parameters was carried out by exponential errors following a log-normal distribution. To describe the residual variability, different error models were tested (additive, proportional or mixed error). Plasma concentrations below the LLOQ were replaced by the LLOQ/2 value.
Covariate models. Two types of covariates were tested during the analysis: continuous and categorical. Graphical methods were used to define the relationship between individual pharmacokinetic parameters (post hoc or conditional estimates) and covariates. Univariate analysis was used to test relevant demographic covariates (body weight, age, sex): they were entered one by one into the population model. The following equation has been used to implement continuous covariates such as age and weight:
where θ CL is the typical clearance value for a patient with the median covariate value and β CL BW is the power exponent for the continuous covariate. The median value from all the other patients was used if a covariate was missing.
An allometric scaling was tested: parameter estimates were standardized for a mean standard BW. From allometric scaling theory, the power exponents are typically 0.75 for clearance and one for volume of distribution [37] .
The influence of binary covariates, such as sex, was tested according to the following equation:
where Sex equals 1 for a woman and 0 for a man, and β CL Sex is the power exponent for the gender.
Once all covariates of interest have been tested in the model (forward selection), each covariate is removed (backward elimination), one at a time. The model was tested again and the objective function (OFV) was collected. To assess whether the difference in the objective function between the basic model and the complete (more complex) model was significant, the likelihood ratio test was used. The difference in À2 log likelihood (OFV) between the basic model and the complete model is approximately χ 2 distributed, with degrees of freedom equal to the difference in number of parameters between the two hierarchical models. Additional parameters leading to a decrease in the objective function of 3.84 were considered significant (P < 0.05). During the back-up elimination phase, only the covariates that resulted in an objective function difference of at least 6.63 (P < 0.01) were retained in the final model. The criteria for selecting a covariate were as follows (i) minimal decrease of 6.63 units in the objective function value (log-likelihood ratio test after χ 2 with 1 degree of freedom, P < 0.01), (ii) reduced variability of the pharmacokinetic parameter (s), and (iii) physiologically plausible effect. The SNPs were checked for quality control with three examinations: (i) a Hardy-Weinberg equilibrium test with a P > 0.05 level; (ii) a frequency test [minor allele frequency (MAF) > 0.01]; and (iii) a percentage of non-missing genotype that was >95%. Genetic covariates were then integrated and tested in the models. Patients were grouped into three class: homozygous for common alleles, heterozygous for the rare allele, and homozygous for the rare allele. Additive, recessive or dominant genetic models were used to assess the influence of genetic polymorphisms on individual pharmacokinetic parameters.
Model evaluation. Graphical evaluation of the goodness of fit was carried out by diagnostic graphics: observed vs. predicted concentrations and weighted residuals (WRES) vs. time and/or predicted concentrations (PRED). Diagnostic graphics and distribution statistics have been produced using RfN (see http://wfn.sourceforge.net) of the R program.
The stability of the model and accuracy of the parameters were assessing by a bootstrap method implement in Wings for NONMEM. The principle of a bootstrap method is to create from the original data set of n individuals, 1000 bootstrap sets of n individuals. For each bootstrap sample, the population pharmacokinetic parameters are estimated. From those, statistics parameters for the whole bootstrap set are defined. The model is validated if the parameters from the bootstrap are closed from those of the original population. Wings for NOMEM (http://wfn.sourceforge.net/) is the software used to perform the bootstrap method. This analysis also produced statistics of the population parameters.
Another step to check the model was the predictioncorrected visual predictive check (PC-VPC) [38] to compare simulated FTC concentrations and observed data [38] . The 5th, 50th and 95th percentiles of the observed data were overlaid on the 90% confidence interval of the 5th, 50th and 95th simulated percentiles, and a visual inspection was performed.
The model was also appraised by the normalized prediction distribution errors (NPDE) metrics [39] .
Exposure-response relationship: infection events. All morbid events (severe and non-severe validated) occurring in children were collected and retrospectively validated by an expert committee; these events were categorized into four classes: malaria, pneumonitis bacterial infection, gastroenteritis and otorhinolaryngology pathology. Time-toevent analysis for occurrence of infection was performed using multivariate Cox regression analyses with R software [R package lme4; D. Bates, M. Maechler, B. Bolker, and S. Walker (http://cran.rproject.org/web/packages/lme4/index. html)]. The relationship between TMP and SMX Bayesian exposures (AUC) and occurrence of infection was assessed after adjusting for age and stratification by study centre. In this time to event analysis, AUC were calculated on three occasions (i.e., M6, M19 and M25) with individual covariates. Dose simulations. For dose simulation, a dummy data set was generated that included 12 000 subjects with one observation each. Each subject's bodyweight was drawn from a uniform distribution between 5 and 16 kg. For SMX, the proportion of slow metabolizers was fixed at 23%, close to the expected proportion reported in sub-Saharan Africa. Monte Carlo simulations (for SMX, 770 and 230 replicates of this database for normal and slow metabolizers, respectively) were performed using the final model. Two cotrimoxazole dose regimens (mg kg À1 ) were investigated, assuming that only formulations with a 5:1 ratio SMX-TMP are available: SMX/TMP, (I) 30/6, (II) 25/5, once daily. For both drugs, the optimal targets (AUC) were fixed to previously reported values in adults using a preventive dose [40] . The 5th, 50th and 95th percentiles of AUC obtained from simulated doses were then overlaid on the reported adult AUC (mean ± 2 SD) using the R program, and a visual inspection was performed.
Results
Pharmacokinetic sub-study characteristics
A total of 136 patients were included in this PK sub-study (73 boys and 63 girls; 53.6% and 46.3%, respectively). The inclusion process has been described elsewhere [29, 41] . At pharmacokinetic evaluations, age ranged from 8 months to 4 years (median age, 1.9 years), and the median body weight was 9.5 kg (minimum and maximum, 6 and 16.3 kg, respectively). Data on a total of 482 plasma concentrations were gathered (mean, 3.5 samples; range, 1-7 samples per child). Median SMX dose was 200 mg and median TMP dose was 40 mg. Patient characteristics are summarized in Table 2 .
Pharmacogenetics results
Three groups were made to categorize the children: homozygotes for the common alleles, heterozygotes for the rare allele and homozygous for the rare allele. The proportion of patients into these groups for CYP2C9, NAT1 and NAT2 genotypes are presented in Table 3 . For 29 children, genetic data were missing. All nine SNPs passed the quality control checks and were further tested in the model.
Population pharmacokinetics
All concentrations were at steady state, and the concentrations in 26 (5.4%) plasma samples for TMP and in 22 (4.5%) for SMX were below the limit of quantification (LLOQ).
SMX model. The best model to describe plasma SMX concentrations was a one-compartment model with first order absorption and elimination. Residual variabilities were best described by a proportional error model.
Gender, age, creatinine, ASAT and ALAT have no effect on the objective function value (OFV). Allometry and NAT1 polymorphisms decreased the OFV significantly. The most significant covariate effect was the effect of allometry on CL/F and on V/F, decreasing the OFV by 31 units, and then on the effect of NAT1 polymorphism (rs1057126) on CL/F, with an additional decrease of 7.8 units. The effect of polymorphism of the enzyme NAT1 on the SMX clearance is only 20%. Table 4 summarizes the final population pharmacokinetics estimates. The final model was fitted on 107 children. All the pharmacokinetics parameters were well estimated, with a relative standard error (RSE) < 30%, RSEs for variability were moderately estimated because they were below 50%.
TMP model. The best model to describe plasma TMP concentrations was a one-compartment model with first order absorption and elimination. Residual variabilities were best described by a proportional error model.
Gender, age, creatinine, ASAT, ALAT have no effect on the OFV. The final model included weight effect on apparent parameters using allometric scaling. The final population pharmacokinetics estimates are summarized in Table 4 . All the pharmacokinetics parameters were well estimated, with an RSE < 30%, RSEs for variability were moderately estimated because they were below 50%. 
Model evaluation
The estimation of the parameters and their associated between-subject variability (BSVs) has been made with precision. Moreover, the confidence intervals (CI) derived from the bootstrap analysis were suitably narrow and did not include the value 0. The PC-VPC results of the final models are satisfactory since the mean prediction corresponded to the observed concentration-time rates and the variability was reasonably estimated (Figure 1) . The NPDE performed on the final models are showed in Figure 2 .
Exposure-response relationship: infection events
A total of 315 hospitalizations were registered in 116 children. A malaria infection had developed in 64 children (47%). A pneumonitis bacterial infection had developed in 31 children (37%). Twenty-three children (17%) had gastroenteritis and 51 (23%) had otorhinolaryngology pathology.
Results for Cox regression univariate analyses showed a correlation between malaria infection and SMX exposure (P = 0.0162), which disappeared after adjustment on the study centre and on age (P = 0.1). No correlation was found between TMP and SMX exposures and bacterial infections (P = 0.52), gastroenteritis (P = 0.68), and otorhinolaryngology pathology (P = 0.44).
Individual exposure to TMP and SMX SMX and TMP AUC were respectively 434.2 ± 13.5 mg l À1 h À1 and 14.3 ± 0.3 mg l À1 h À1 , whereas they were respectively 577.7 ± 21.1 mg l À1 h À1 and 22.2 ± 1.1 mg l À1 h À1 in the study by Amina et al. [40] . These preliminary results comparing AUC show that children are under-dosed compared to adults. For both molecules, a unique dose of 200/40 mg recommended by the WHO for the 6-13.9 kg children lead to under-dosing in SMX and TMP for children from 10 to 15 kg. If we seek to have exposure comparable to that of an adult, it will be necessary to adjust children's dosage.
TMP and SMX dose adjustment simulations
To simulate the exposure (AUC 0-24 ) for the current dosage recommendations, the final model was applied. The simulation results are shown in Figure 3 . For SMX, simulated regimens of 30 mg kg À1 in the 5-10 kg group and 25 mg kg À1 in the 10-15 kg group seem to be the more appropriate dose. In the same way for TMP, simulated regimens of 6 mg kg À1 in the 5-10 kg group and 5 mg kg
À1
in the 10-15 kg group seem to be the more appropriate dose. Our simulations show that dosage in mg kg À1 seems more appropriate in order to have an exposure comparable to that in adults.
Discussion
To describe cotrimoxazole pharmacokinetics in a large population of West African HIV-infected children, a population approach was used. Our main result shows that the current WHO dosage recommendations of cotrimoxazole underexposed the 10-15 kg children compared to adults. TMP half-life found in our study is comparable to that previously observed in children by Hoppu et al. and Siber et al. [25, 26] . For SMX, the half-life in our study is shorter than that previously observed by Siber et al. [17] . However, Table 4 Population pharmacokinetic parameters of SMX and TMP from the final model their population comprised children with normal and impaired renal function. In this infant cohort, weighting 5-16 kg, the weight-based allometric scaling of CL and V has been chosen for both SMX and TMP models. An age-related maturation effect has been investigated but was not relevant. The effects of maturation are usually observed in children less than one-year-old and there were very few children of this age in the cohort.
For the SMX, the effect of NAT1 polymorphism decreases drug clearance whereas there is no difference for NAT2 and CYP2C9 polymorphisms. Kagaya et al. showed a significant impact of NAT2 on SMX CL whereas no effect of CYP2C9 polymorphism was observed [23] . The difference between our studies could be explained by the relatively low impact of each of these pathways. In our study, for example, the effect of the enzyme NAT1 on SMX clearance is only around 20% and does not require a dose adjustment.
Cotrimoxazole is a widely available, easy to administer, safe and low-cost antibiotic that still appears as first-line drug in developing countries. Our study of PK/PD survival showed no Figure 2 SMX (at the top) and TMP (at the bottom) NPDE Figure 1 SMX (on the left) and TMP (on the right) prediction-corrected visual predictive check: comparison between the 5th (lower dashed line), 50th (solid line) and 95th (upper dashed line) percentiles obtained from 1000 simulations and the observed data (points) for SMX or TMP concentrations correlation between the SMX or the TMP AUCs and the infection occurrence. This could be explained by the lack of statistical power due to the number of events in these children already on antiretroviral therapy for 6 months with an increased immunological response [29] . Even if the cotrimoxazole has proved its effect, there are still hospital admissions due to opportunistic infections. Children cotrimoxazole exposures were lower than those of adults. This could suggest an issue in the dosing regimen.
Given the limited pharmacokinetic data in the literature, concentrations for preventive efficacy target and toxicity relationships have never been studied. The only known concentration target is for curative dosage in the case of infections by Pneumocystis jirovecii, and is 150-200 mg l À1 for SMX and 3-8 mg l À1 for TMP [42] . For a preventive dosing regimen, minimum inhibitory concentration (CMI) thresholds are well below these, especially since Hughes et al. have shown that SMX-TMP combination is highly effective in the prevention of P. carinii pneumonitis [6] . However, in practice, for therapeutic monitoring, the dosage adjustment of cotrimoxazole is performed with reference to the concentrations of SMX [43] , while TMP is connected to the toxicity [43] . As there are no preventive target concentrations, we took as reference the AUC in adults associated with preventive doses. Our study shows that children are clearly under-dosed in cotrimoxazole. Other recommended regimens were simulated in order to obtain exposures similar to those of adults. Simulations show that regimens of 30 mg kg À1 of SMX and 6 mg kg À1 of TMP in the group of 5-10 kg and 25 mg kg
À1
of SMX and 5 mg kg À1 of TMP in the group of 10-15 are more appropriate doses. All these simulations are effective in a population comparable to that of our study, i.e. in a child population at risk of underfeeding. All these simulations are preliminary because the risk-benefit ratio of such a change of dose should be evaluated for each patient before considering a change in dosage. Furthermore, the WHO recommends an 'easier' scheme in resource-limited settings.
In conclusion, this work originally set out to describe the pharmacokinetics of cotrimoxazole in a substantial number of HIV-infected children, with a population approach. Our simulations of the WHO recommended regimens have demonstrated in SMX and TMP exposures much lower for children compared to adults, leading potentially to reduced effectiveness of cotrimoxazole in these children. To achieve comparable exposure to adults, a dosing scheme per kg is proposed: 30-6 mg kg À1 in the 5-10 kg group and 25-5 mg kg À1 in the 10-15 kg group for SMX-TMP. This suggested adapted dose per kg scheme should be investigated and prospectively confirmed.
